基层医院中糖尿病与心血管疾病共病现状与 影响因素分析
Analysis of the Current Situation and Influencing Factors of Comorbidity of Diabetes and Cardiovascular Disease in Primary Hospitals
DOI: 10.12677/acm.2026.1662455, PDF,    科研立项经费支持
作者: 陈 琳, 金文琪:聊城市东昌府人民医院内分泌科,山东 聊城;时 雪, 徐 潮*:山东第一医科大学附属省立医院内分泌代谢病科,山东 济南;李 森:聊城市人民医院内分泌科,山东 聊城
关键词: 基层医院农村地区2型糖尿病主要不良心血管事件危险因素Primary Hospitals Rural Areas Type 2 Diabetes Mellitus Major Adverse Cardiovascular Events Risk Factor
摘要: 目的:探讨农村地区T2DM患者发生主要不良心血管事件(MACE)的危险因素。方法:采用真实世界观察性研究,纳入488名农村T2DM患者,收集基线资料并随访2年,通过多因素Cox回归分析以识别MACE的危险因素。结果:2年随访期间,51.64%的患者发生MACE,其中基线有MACE病史的患者复发率为73.56%,无MACE病史的患者新发率为39.49%。多因素分析显示,病程、糖化血红蛋白(HbA1c)、低密度脂蛋白胆固醇(LDL-C)达标率、同型半胱氨酸(HCY)、尿微量白蛋白(MAU)、尿白蛋白/肌酐比值(UACR)和空腹胰岛素(FINS)是MACE的独立危险因素。新型降糖药物使用率低,且与MACE风险增加相关。结论:T2DM病程、血糖控制不佳及肾损害是MACE的重要危险因素。基层医院应推广具有心血管保护作用的降糖药物,以降低MACE风险。
Abstract: Objective: To explore the risk factors for major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM) in rural areas. Methods: A real-world observational study was conducted, enrolling 488 rural T2DM patients. Baseline data were collected, and participants were followed for 2 years. Multivariate Cox regression analysis was performed to identify risk factors for MACE. Results: During the 2-year follow-up, 51.64% of patients developed MACE, with a recurrence rate of 73.56% in those with a baseline history of MACE and an incidence rate of 39.49% in those without prior MACE. Multivariate analysis revealed that disease duration, glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C) compliance rate, homocysteine (HCY), urinary microalbumin (MAU), urinary albumin-to-creatinine ratio (UACR), and fasting insulin (FINS) were independent risk factors for MACE. Novel hypoglycemic agents exhibited low utilization rates and were associated with an increased risk of MACE. Conclusion: Prolonged T2DM duration, poor glycemic control, and renal impairment are critical risk factors for MACE. Primary hospitals should promote the use of hypoglycemic agents with cardiovascular protective effects to mitigate MACE risk.
文章引用:陈琳, 时雪, 金文琪, 李森, 徐潮. 基层医院中糖尿病与心血管疾病共病现状与 影响因素分析[J]. 临床医学进展, 2026, 16(6): 2329-2337. https://doi.org/10.12677/acm.2026.1662455

参考文献

[1] Einarson, T.R., Acs, A., Ludwig, C. and Panton, U.H. (2018) Prevalence of Cardiovascular Disease in Type 2 Diabetes: A Systematic Literature Review of Scientific Evidence from across the World in 2007-2017. Cardiovascular Diabetology, 17, Article No. 83. [Google Scholar] [CrossRef] [PubMed]
[2] Xiao, Y., Yu, B., Chao, C., Wang, S., Hu, D., Wu, C., et al. (2024) Chinese Expert Consensus on Blood Lipid Management in Patients with Diabetes (2024 Edition). Journal of Translational Internal Medicine, 12, 325-343. [Google Scholar] [CrossRef] [PubMed]
[3] American Diabetes Association (2019) 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes2020. Diabetes Care, 43, S14-S31. [Google Scholar] [CrossRef] [PubMed]
[4] Cai, C., Liu, Y., Li, Y., Shi, Y., Zou, H., Bao, Y., et al. (2022) Effectiveness of Quality of Care for Patients with Type 2 Diabetes in China: Findings from the Shanghai Integration Model (SIM). Frontiers of Medicine, 16, 126-138. [Google Scholar] [CrossRef] [PubMed]
[5] Tsai, I., Wang, C., Lu, Y., Hung, W., Wu, C., Lu, L., et al. (2017) The Burden of Major Adverse Cardiac Events in Patients with Coronary Artery Disease. BMC Cardiovascular Disorders, 17, Article No. 1. [Google Scholar] [CrossRef] [PubMed]
[6] Duan, D., Kengne, A.P. and Echouffo-Tcheugui, J.B. (2021) Screening for Diabetes and Prediabetes. Endocrinology and Metabolism Clinics of North America, 50, 369-385. [Google Scholar] [CrossRef] [PubMed]
[7] Au Yeung, S.L., Luo, S. and Schooling, C.M. (2018) The Impact of Glycated Hemoglobin (HbA1c) on Cardiovascular Disease Risk: A Mendelian Randomization Study Using UK Biobank. Diabetes Care, 41, 1991-1997. [Google Scholar] [CrossRef] [PubMed]
[8] 李亚冬, 李雅君. 不同糖代谢状态下糖化血红蛋白与冠心病的相关性研究[J]. 心肺血管病杂志, 2023, 32(1): 53-56.
[9] Jiao, X., Zhang, Q., Peng, P. and Shen, Y. (2023) Hba1c Is a Predictive Factor of Severe Coronary Stenosis and Major Adverse Cardiovascular Events in Patients with Both Type 2 Diabetes and Coronary Heart Disease. Diabetology & Metabolic Syndrome, 15, Article No. 50. [Google Scholar] [CrossRef] [PubMed]
[10] 何健祥. 糖化血红蛋白在2型糖尿病诊断和治疗中的应用价值研究[J]. 检验医学与临床, 2020, 17(5): 695-697.
[11] 中国老年学和老年医学学会. 老年冠心病慢病管理指南[J]. 中西医结合研究, 2023, 15(1): 30-42.
[12] 李雷, 孙怡咪, 刘刚. 冠脉CTA定量参数与冠心病患者疾病进展和预后的关系[J]. 海南医学, 2022, 33(20): 2672-2675.
[13] Chen, J., Jiang, C., Guo, M., Zeng, Y., Jiang, Z., Zhang, D., et al. (2024) Effects of SGLT2 Inhibitors on Cardiac Function and Health Status in Chronic Heart Failure: A Systematic Review and Meta-Analysis. Cardiovascular Diabetology, 23, Article No. 2. [Google Scholar] [CrossRef] [PubMed]
[14] Popoviciu, M., Păduraru, L., Yahya, G., Metwally, K. and Cavalu, S. (2023) Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. International Journal of Molecular Sciences, 24, Article 10449. [Google Scholar] [CrossRef] [PubMed]
[15] Müller, T.D., Finan, B., Bloom, S.R., D’Alessio, D., Drucker, D.J., Flatt, P.R., et al. (2019) Glucagon-Like Peptide 1 (GLP-1). Molecular Metabolism, 30, 72-130. [Google Scholar] [CrossRef] [PubMed]
[16] Neuen, B.L., Heerspink, H.J.L., Vart, P., Claggett, B.L., Fletcher, R.A., Arnott, C., et al. (2024) Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared with Conventional Care in Patients with Type 2 Diabetes and Albuminuria. Circulation, 149, 450-462. [Google Scholar] [CrossRef] [PubMed]